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ABSTRACT
Background and aims Behavioural and pharmacological support for smoking cessation improves the chances of
success and represents a highly cost-effective way of preventing chronic disease and premature death. There is a large
number of clinical stop-smoking services throughout the world. These could be connected into a global network to provide
data to assess what treatment components are most effective, for what populations and in what settings. To enable this, a
minimum data set (MDS) is required to standardize the data captured from smoking cessation services globally.
Methods We describe some of the key steps involved in developing a global MDS for smoking cessation services and
methodologies to be considered for their implementation, including approaches for reaching consensus on data items to
include in a MDS and for its robust validation. We use informal approximations of these methods to produce an example
global MDS for smoking cessation. Our aim with this is to stimulate further discussion around the development of a global
MDS for smoking cessation services. Results Our example MDS comprises three sections. The ﬁrst is a set of data items
characterizing treatments offered by a service. The second is a small core set of data items describing clients’ characteris-
tics, engagement with the service and outcomes. The third is an extended set of client data items to be captured in addition
to the core data items wherever resources permit. Conclusions There would be beneﬁt in establishing a minimum data
set (MDS) to standardize data captured for smoking cessation services globally. Once implemented, a formal MDS could
provide a basis for meaningful evaluations of different smoking cessation treatments in different populations in a variety
of settings across many countries.
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INTRODUCTION
Despite the prevalence of tobacco use decreasing in many
countries, there are still more than 1 billion tobacco users
world-wide [1], and this number is not falling. This is partly
because of increasing prevalence in other countries and
partly because of population growth. Some of these users
may be able to stop when they choose, but the success rates
of unaided quit attempts [2] and ﬁndings from clinical trials
and population studies [3] indicate that most would beneﬁt
from support in their attempt to stop smoking. Article 14 of
the World Health Organization Framework Convention on
Tobacco Control (FCTC) requires Parties to take effective
measures to promote tobacco use cessation and adequate
treatment for tobacco dependence. Guidelines for the
implementation of Article 14 were adopted in November
2010 and outline what is needed to enable Parties to meet
their obligations under that Article [4]. Current evidence,
however, indicates that only a small minority of countries,
and very few low- and middle-income countries, have the
infrastructure and systems elements in place to be able to
meet these obligations [5,6].
Studies in some high-income countries suggest that
speciﬁc medicines and types of behavioural support can
improve smokers’ chances of long-term success at stopping
[7]. However, in order to apply this work globally we ideally
need to know more about their effectiveness throughout
the world. More broadly, there is considerable room for
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improvement in stop-smoking support in all settings. We
need to build incrementally on our understanding of how
combinations of behaviour change techniques, delivered
in what way, to what kinds of smoker and in what settings
provide the optimal outcomes [7].
In the future, the challenge for tobacco use cessation
will be to improve upon the strategies currently available
and, more importantly, to identify support options that
are clearly effective, cost-effective and affordable in different
populations and different regions. Randomized controlled
trials (RCTs) can only take us so far with this, and suffer
from the well-established limitations of generalizability,
practicability, cost and time-scale [8]. A programme of
research is required, complementing the existing evidence
base from RCTs, to provide vital information about what
approaches work most effectively throughout a broad
range of settings. This programme should consist of
quasi-experimental and epidemiological studies that exam-
ine variations in smoking cessation outcomes among
different cohorts of smokers using different methods of
quitting, adjusting for as many confounding factors as
possible [9]. This kind of approach has already paid
dividends in the United Kingdom, where the combination
of a common national standard for outcome assessment
[10] and the centralized collection of mandatory smoking
cessation service (performance data by the Health and
Social Care Information Centre, now NHS Digital) has
enabled conﬁrmation of ﬁndings from RCTs concerning
the relative effectiveness of different forms of medication,
and identiﬁcation of speciﬁc treatments with improved
success rates [11].
Our vision is to extend the success of the approach used
in the United Kingdom (where there is still scope for
capturing and using more data about treatments and
clients for further analyses and optimization of services),
and to deploy it globally. By connecting clinical smoking
cessation services from many countries to form a global
network of service providers, it will be possible to share
information about the performance of different treatments
in different scenarios within a common frame of reference,
and to assess and identify optimal treatment strategies for
different populations in different settings on a global scale.
A key step in connecting providers to form a global
network will be establishing a minimum data set (MDS)
that should be captured by all clinical smoking cessation
services in the network. The use of MDSs for the standard-
ized capture of data is widespread inmany aspects of health
care, from the treatment and management of individual
clinical conditions [12] and speciﬁc health-care procedures
[13] to entire disciplines [14].MDSs have also been used for
evaluating smoking cessation services at a national level in
a number of countries [15,16].
Our aim here is to highlight the need for a global MDS
for smoking cessation services, and to outline the steps
towards developing a data set that can be used by all ser-
vices, in all territories, of all countries. We describe a num-
ber of methods that could be used to produce this global
MDS. We also provide an example of what a global MDS
for smoking cessation could look like. Our intention is not
to propose this as a candidate for a global MDS, as more
thorough applications of the methodologies described, ro-
bust validations and detailed considerations of issues such
as cross-cultural differences are required to achieve this.
Rather, we hope that it will stimulate further discussion
concerning the need for a global MDS, and how best to
achieve this.
An important aspect of the MDS is that it will be
designed to be completed by the people that operate the
smoking cessation services. This sets it apart from surveys
gathering data for global initiatives for evaluating tobacco
use and control, such as the World Health Organization
(WHO)’s Framework Convention on Tobacco Control [17]
and Global Adult Tobacco Survey [18], which are designed
to be completed by governments and policy setters, and
aim typically to capture larger volumes of more complex
data. There will, however, be important lessons to be learnt
from experiences with these surveys, including a range of
cross-cultural issues [19].
METHODS
A variety of methods can be used to develop a MDS [20].
Most begin with some form of bottom-up identiﬁcation of
candidate data items. This can include interviews with
expert and stakeholder groups [21] and reviews of existing
information systems and data sets [14]. This is followed by
a second stage, in which there is an iterative process of
consolidation which aims to achieve consensus on optimal
items, resolve conﬂicts and harmonize language, descrip-
tions and formats, etc. One formal technique used increas-
ingly for this second stage is Delphi [22]; for examples see
Ireland et al. [14] and Ranegger et al. [23]. Finally, proposed
data sets need to be validated. Again, a number of
approaches are possible, most of which involve review by
additional groups of experts and stakeholders, with
methods such as the Nominal Group Technique [24] used
to reach consensus on the applicability of items in data sets.
The development of a formal global MDS for smoking
cessation will need to follow these lines, using robust
methods to identify and validate data sets, with particular
attention given to testing of cross-cultural aspects.
In order to stimulate discussions around the need for
such MDS and the form this might take, we used informal
approximations of these methods to produce an example
global MDS for smoking cessation services. We used
existing smoking cessation data sets from the UK’s Stop
Smoking Services and MDSs from other countries to
identify candidate data items. To minimize repetition of
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treatment-speciﬁc data, we deﬁned separate data sets that
describe the treatments offered by services, and the client’s
engagement with the various treatments offered by a
service.
For the treatment data, we took as our starting point a
list of behaviour change techniques found in UK Stop
Smoking Services (SSS) [25]. From this we selected only
those treatment features found to be associated with
improved quit outcomes [either self-reported or carbon
monoxide (CO)-veriﬁed]. For client data, we began with
the data items listed in the latest version (version 9) of
the UK’s National Centre for Smoking Cessation and Train-
ing’s Stop Smoking Service Client Record Form [26]. This
template form has all the data items required for the
routine performance assessment conducted of UK smoking
cessation services. The form has some limitations; for
example, there is possible ambiguity in how to complete
items such as: ‘are you being treated for physical or mental
health problems’, and it is possible that if an individual has
a problem but is not being treated that the problemwill not
be recorded. However, any approach to asking these ques-
tions that attempts to balance accuracy of data with sensi-
tivity concerning what constitutes a problem, in the
absence of a full diagnostic procedure, will encounter some
issue of this kind. The data required to describe a client’s
engagement with smoking cessation services can be exten-
sive, and regional differences in resources (e.g. computer
equipment, network infrastructure, measurement devices)
will mean that the extent of data that can be captured by
services will vary. We therefore propose, rather than a
single client data set, a core set of data that could be
captured in every smoking cessation service setting, and
an extended, richer set of data items that could be captured
wherever resources make this possible. Our sample MDS
therefore comprises the treatment data, the core client data
and the extended client data.
Data sets were then reﬁned with reference to existing
smoking cessation MDSs, namely the Scottish smoking
cessation MDS [15] and the MDS for evaluation of North
American smoking quitlines [16]. Through an informal,
iterative process of review and modiﬁcation all authors,
who have extensive experience of international smoking
cessation services and epidemiological studies of tobacco
use, then reﬁned the example data sets further, and
reached consensus on their contents. When developing a
formal MDS a formal process for iteratively reaching
consensus, such as Delphi [22], should be considered for
this stage.
To provide some level of cross-cultural validation, we
then sought feedback on the example data sets from
colleagues in the International Cooperation Centre for
the Framework Convention on Tobacco Control in
Uruguay and the Centre for Tobacco Studies in Syria.
Feedback was provided by one representative from each
organization. In both cases the feedback was positive, with
agreement that the choice of data items for each data set
was broadly appropriate for those services in those settings.
Issues raised included the limited availability of CO
measurement in some regions, labels used for some data
items (e.g. ‘gender’ would be more acceptable than ‘sex’),
and how best to capture some data (e.g. ‘age’ would be
preferable to ‘date of birth’). The example data sets were
updated accordingly. Again, the process used to reach
agreement for the sample MDS was informal, but formal
approaches such as Nominal Group Technique should be
considered when developing the formal MDS.
In broader cross-cultural terms, it is important to note
that not all countries have sufﬁcient infrastructure to
support dedicated clinical smoking cessation services. In
those that do not, there is often more of a focus on delivery
of opportunistic brief advice supporting smoking cessation
through alternative existingmechanisms, such as tubercu-
losis clinics [27,28]. These brief advice approaches vary
considerably from the services offered by smoking cessation
clinics, largely because they are not designed to follow-up
and track client quit attempts. The data describing brief
advice approaches will therefore vary signiﬁcantly from
data describing clinical smoking cessation service, and we
suggest that deﬁning minimum data sets for brief advice
approaches might best be handled as a separate (but
linked) activity.
RESULTS
Example treatment data that should be captured once for
each treatment a service offers are shown in Table 1.
Example core client data that should be captured in every
clinical smoking cessation service setting are shown in
Table 2. Example extended client data that should be
captured where resources permit are shown in Table 3.
DISCUSSION
While individual tobacco cessation services using locally
deﬁned measures and methods may be effective to some
degree, harmonizing the data captured throughout
services will make it possible to assess the effectiveness of
different treatments in different regions, to identify optimal
sets of approaches for supporting smoking cessation in ava-
riety of different settings and to commission more effective
and cost-effective measures that can reach more smokers
and increase quit rates. This approach has proved success-
ful in the United Kingdom through standardization of out-
come assessments and the use of common data structures
in the systems supporting services, although there is still
scope for capturing additional data for further analyses
and service optimization. Our vision is to extend this
approach and deploy it internationally. To enable this
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Table 1 Treatment information (one record per type of treatment on offer).
Item label Deﬁnition Response options
Name of service Name of current service Free text
Name of subservice Name of component of current service Free text
Service setting Type of environment in which service is
delivered
One from: community/ psychiatric/
hospital/ pharmacy/ dental/ general
practice/maternity/ children’s centre/
educational/ prison/military base/ other
Treatment mode The mode of the treatment provided One from: closed group/ couple/family/
telephone/text message/support/ one-
to-one support/open (rolling) group/
drop-in clinic
Average session length Length of sessions in minutes, taking
account of the fact that the ﬁrst session is
often longer
Length in minutes
Number of sessions Total number of sessions Number of sessions
Frequency of sessions Number of sessions per week Number of sessions/week
Duration of behavioural support Number of weeks post-quit date that
support is provided
Number of weeks
Content of behavioural support
Strengthen ex-smoker identity Advise on the importance of ‘not a puff
no matter what’ and starting to consider
smoking as ‘not an option’
Yes/No
Elicit client views Check client’s understanding and ensure
that s/he has an opportunity to ask
questions and express concerns
Yes/No
Measure CO At the ﬁrst session this provides an
indication to the smoker and the
practitioner of the degree of toxin
exposure from smoking; after the quit
date provides conﬁrmation of smoking
abstinence
Yes/No
Explain the purpose of CO monitoring Provides motivation to the client not to
smoke after the quit date and rewards
the client for not smoking
Yes/No
Give options for additional and later
support
Offer additional phone or text message
support
Yes/No
Provide rewards contingent upon
stopping smoking successfully
Be fulsome in praise for not smoking at
each post-quit visit
Yes/No
Advise on changing routine Discuss with the client, and get
agreement to, ways of avoiding speciﬁc
smoking triggers
Yes/No
Facilitate relapse prevention and
coping
Discuss with client speciﬁc ways of
dealing with cravings when they arise
without smoking
Yes/No
Advise on stop smoking medicine Try to ensure that the smoker agrees to
use the most effective stop-smoking
medication available in the locality
(ideally either varenicline or NRT patch
plus a faster acting product)
Yes/No
Ask about experiences of stop
smoking medication that the smoker
is using
Check that the client is using the stop-
smoking medication properly and
address any concerns about adverse
effects
Yes/No
Advise on conserving mental
resources
Advise on how to ensure that client gets
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vision, a minimum data set is required for the standardized
capture of data from smoking cessation services globally. In
this study, we take the ﬁrst steps towards this by
highlighting the need for a global MDS for smoking cessa-
tion services, and outlining some of the key steps andmeth-
odologies that should be considered in developing this.
To stimulate further discussion concerning the need
and development of a global MDS for smoking cessation,
we used informal approximations of some of the methods
discussed here to produce an example MDS. To be clear,
our aim with this is to facilitate further detailed discussion
about the development of a global MDS; we are not
suggesting this be considered as a proposal for a formal
global MDS. The informal approaches used to develop this
sample MDS lack the rigour of the formal approaches we
have suggested. Development of a proposal for a global
MDS will require the full application of these formal tech-
niques for identifying candidate data sets and achieving
consensus among experts and stakeholders, robust tech-
niques for evaluation of proposed data sets and detailed
assessments and testing of cross-cultural factors. Cross-
cultural aspects will be important, and should consider
issues such as: variations in resources for, and acceptability
of, capturing data items between countries and between
territories with varying resources within countries; issues
around data integrity and ownership; and regional differ-
ences in tobacco use. These issues should be given particu-
lar attention when considering how the MDS will be used
Table 1. (Continued)
Item label Deﬁnition Response options
Advise on/facilitate use of social
support
Discuss with client ways in which s/he




Provide a summary of the key points of
each session and up to three things to
keep in mind between it and the next
session Conﬁrm client’s decisions and
commitments made during the session
Yes/No
Provide reassurance Address client’s concerns and provide
reassurance that adverse or worrying
experiences are normal and will subside
Yes/No
Boost motivation and self-efﬁcacy Express belief in the client’s ability to
succeed, and help the client to believe
that s/he will succeed
Yes/No
Provide information on withdrawal symptoms Ensure that the client knows what to
expect in terms of the nature, severity
and duration of withdrawal symptoms
Yes/No
CO = carbon monoxide; NRT = nicotine replacement therapy.
Table 2 Core client data.
Item label Deﬁnition Response Options
Age Client’s age in years Integer
Gender Client’s gender Male | Female
Usual daily cigarette
consumption
Number of cigarettes smoked
usually smoked each day
Integer





All of the pharmacological
supports planned to be used by
client
Any from (dummy coded) Varenicline | Bupropion | Cytisine |
Nortriptyline | NRT | Nicotine vapourising device | Other
NRT support used All of the types of NRT planned to
be used by client
Any from (dummy coded) None |Patch | Gum | Lozenge | Nasal Spray
| Mouth Spray | Oral Strips | Inhalator | Microtab | Other
4 weeks: self-report no
puff in past 2 weeks
No smoking at all in the past
2 weeks at 4-week follow up
Yes | No | Lost to follow up
12 weeks: self-report no
puff in past 10 weeks
No smoking at all in the past
4 weeks at the 12-week follow up
Yes | No | Lost to follow up
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Table 3 Extended client data.
Item label Deﬁnition Response options
Adviser information
Adviser ID The service adviser’s unique identiﬁcation
number, assigned by the service’s national
coordinating body
Integer assigned by the system
Venue ID A unique code for the service site, assigned
by the service’s national coordinating body
Integer assigned by the system
Client information
Pre-quit CO reading Measure of carbon monoxide (p.p.m.) in
expelled air before quit attempt
Integer
Pregnant Is the client pregnant? Yes/No
Breastfeeding Is the client breastfeeding? Yes/No
Education level Years of formal education One from: none/primary/secondary/tertiary/Bachelors/
Masters/Doctoral
Occupation Category of client’s occupation One from: managerial/professional/intermediate/routine
and manual/home carer/retired/never worked, long-
termunemployed/unable towork (sick/disabled)/prisoner
Currently treated for physical
health problem?
Is the client currently being treated for any
physical health problems?
Yes/No
Currently treated for mental
health problems?
Is the client currently being treated for any
mental health problems?
Yes/No
Currently treated for drug or
alcohol problem?
Is the client currently being treated for any
alcohol or drug-related problems?
Yes/No
Current medications Any medication the client is currently
taking
Select from ﬁxed list (with typing completion) plus
speciﬁed other
Partner smoking status Does the client’s partner smoke? Yes/no/not applicable
Do others smoke in your
house?
Do people other than your partner smoke in
your house?
Yes/no
Time to ﬁrst cigarette of the
day
How many minutes until client has ﬁrst
cigarette of the day?
One from: within 5 minutes/6–30 minutes/31–60
minutes/> 60 minutes
Willing to quit? Client’s willingness to set a target quit date Yes/no
Self-efﬁcacy Client’s conﬁdence in their ability to quit Five-point scale from 1 (very low) to 5 (very high)
Agreed quit date Date the client plans to stop smoking
completely, with support from service
Day/month/year
How much time currently
spent with urges to smoke
(prior to quitting)?
How much time does the client currently
spend with urges to smoke?
One from: none of the time/a little of the time/some of the
time/a lot of the time/almost all the time
How strong are the urges
(prior to quitting)?
How strong are the client’s urges to smoke? One from: no urges/slight/moderate/strong/extremely
strong
Weeks since most recent quit
attempt
How many weeks since the client’s most
recent attempt to quit smoking?
Integer
How long recent quit attempt
lasted
How many weeks did the client’s most
recent attempt to quit last?
Integer
Past use of stop smoking
medicines
Any medicines the client has used in






Are these used at same time or
consecutively?
One from: used at same time/used consecutively
How client heard about the
service
How the client heard about the service One from: GP/other health professional/friend/relative/
advertising/pharmacy/other
Outcome data
Pre-quit CO reading Measure of carbon monoxide (p.p.m.) in
expelled air before quit attempt
Integer
4 weeks: CO reading Measure of carbon monoxide (p.p.m.) in
expelled air at 4 week visit
Integer
4 weeks: CO veriﬁed 4-week
quitter
Quit status at 4 weeks (< 10 p.p.m.) Yes/No/not available
(Continues)
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in low- andmiddle-income countries, where smoking rates
are rising, and the use of an MDS to facilitate service opti-
mization could potentially have the greatest impact.
We invite comments and suggestions on any aspect of
the development of a global MDS for smoking cessation, in-
cluding which methods will be optimal for development
and validation of the MDS, and speciﬁc cross-cultural as-
pects that should be considered. We propose that these
comments and suggestions be collated by the newly formed
International Centre for Tobacco Cessation (ICTC), a centre
set up to offer countries technical assistance in improving
their tobacco cessation support systems, of which one of
us (M.R.) is director (all communications on this topic
should be addressed to martin@martinraw.com). Beyond
gathering this feedback, the next stages will be to develop
a formal MDS, promote use of the MDS in smoking cessa-
tion services globally, maintain the MDS moving forward
(so that, for example, details of new harm reduction prod-
ucts can be added as they come to market) and collate
and analyse data captured using the MDS from cessation
services. We propose that these tasks should also be han-
dled by the ICTC, although we welcome suggestions for al-
ternative approaches.
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